ARTICLE | Clinical News
Cotara: Phase I data
June 7, 2010 7:00 AM UTC
An open-label, U.S. Phase I trial in 10 patients showed that 1.5, 2 and 2.5 mCi/cm 3 Cotara administered interstitially via convection-enhanced delivery was well tolerated. There was 1 DLT of brain edema at 2.5 mCi/cm 3 Cotara. Dosimetry assessments showed that Cotara concentrated in the tumor with minimal systemic radiation exposure. ...